compound 25(Xuzhou Medical University)

N/A

Report date: 2022/05/23 18:05:02
NME

Base Information

Drug Namecompound 25(Xuzhou Medical University)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVasopressin V2 receptor antagonists
TargetsVasopressin V2 receptor
Therapy Area/IndicationsPolycystic Kidney, Autosomal Dominant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesXuzhou Medical University (Xzmu)
China Registration ClassN/A

Develop Information

Active CompaniesXuzhou Medical University (Xzmu)
Inactive CompaniesN/A
Active IndicationsPolycystic Kidney, Autosomal Dominant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A